Abstract
Sinonasal squamous cell carcinoma (SNSCC) is a rare and aggressive malignancy often excluded from landmark immunotherapy trials. This retrospective study evaluates the clinical activity of immune checkpoint inhibitors (ICIs) in 13 patients with recurrent or metastatic SNSCC. Results indicate a median overall survival of 15.0 months and a subset of patients achieving complete remission, suggesting that ICIs represent a viable therapeutic strategy for this underserved population.
Introduction
Sinonasal malignancies are rare, accounting for only 3% of all head and neck cancers. Sinonasal squamous cell carcinoma (SNSCC) is the most prevalent subtype, typically arising in the maxillary sinus or nasal cavity. Despite advancements in surgical techniques and radiotherapy, the 5-year overall survival rate for SNSCC has remained stagnant at approximately 50% for three decades.
Due to its rarity, SNSCC patients were largely excluded from pivotal trials like KEYNOTE-048, which established immune checkpoint inhibitors (ICIs) as a standard of care for other head and neck squamous cell carcinomas. Consequently, there is a significant data gap regarding the efficacy of these therapies in the anatomically distinct context of SNSCC.
Methods
A retrospective chart review was conducted for patients treated at the USC Norris Comprehensive Cancer Center and Los Angeles General Medical Center between 2016 and 2023. The study included 13 patients with histologically confirmed recurrent or metastatic SNSCC who received systemic ICI therapy. Researchers analyzed demographic data, clinical characteristics, and molecular biomarkers, including PD-L1 expression (Combined Positive Score, CPS), Tumor Mutational Burden (TMB), and Microsatellite Instability (MSI) status. The primary endpoints were median treatment duration and Median Overall Survival (OS).
Results and Discussion
The cohort demonstrated a high prevalence of PD-L1 expression; among patients with known status, 81.8% had a CPS ≥ 1. This high expression provides a strong mechanistic rationale for ICI use. Additionally, biomarker analysis revealed that 30.8% of patients were TMB-high and 15.4% were MSI-high, identifying a subset of patients who may be particularly immunogenic and responsive to ICI therapy.
Pembrolizumab was the most frequently utilized ICI (92.3%). Treatment was administered as first-line therapy in 53.8% of cases and second-line or beyond in 46.2%.
The median Overall Survival (OS) was 15.0 months (95% CI 4.4 – 57.0), with a median treatment duration of 5.5 months. Notably, 15.4% (n=2) of patients achieved a Complete Remission (CR) and discontinued therapy, while another 15.4% remained on treatment at the time of analysis. Most discontinuations (69.2%) were due to disease progression rather than toxicity, suggesting that ICIs are generally well-tolerated in this population.
Conclusion
This study provides preliminary evidence of clinical activity for ICIs in recurrent/metastatic SNSCC. While limited by a small sample size (N=13) and its retrospective nature, the findings highlight the potential for long-term responses in a subset of patients. Future prospective clinical trials and refined biomarker identification are necessary to optimize patient selection and improve outcomes for this rare disease.
Summary updated